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Background: Pain is a significant public health concern, and current
pharmacological treatments have problematic side effects and limited
effectiveness. N-methyl-D-aspartate (NMDA) glutamate receptor
antagonists have emerged as one class of candidate treatments for pain
because of the significant contribution of glutamate signalling in
nociceptive processing.
Methods: This study compared effects of the NMDA receptor
antagonists ketamine and MK-801 in assays of pain-stimulated and
pain-depressed behaviour in rats. The nonsteroidal anti-inflammatory
drug ketoprofen was examined for comparison as a positive control.
Intraperitoneal injection of dilute acid served as an acute visceral
noxious stimulus to stimulate a stretching response or depress
intracranial self-stimulation (ICSS) in male Sprague–Dawley rats.
Results: Ketamine (1.0–10.0 mg/kg) blocked acid-stimulated stretching
but failed to block acid-induced depression of ICSS, whereas MK-801
(0.01–0.1 mg/kg) blocked both acid-stimulated stretching and acid-
induced depression of ICSS. These doses of ketamine and MK-801 did not
alter control ICSS in the absence of the noxious stimulus; however, higher
doses of ketamine (10 mg/kg) and MK-801 (0.32 mg/kg) depressed all
behaviour. Ketoprofen (1.0 mg/kg) blocked both acid-induced stimulation
of stretching and depression of ICSS without altering control ICSS.
Conclusion: These results support further consideration of NMDA
receptor antagonists as analgesics; however, some NMDA receptor
antagonists are more efficacious at attenuating pain-depressed behaviours.
What does this study add? NMDA receptor antagonists produce
dissociable effects on pain-depressed behaviour.
Provides evidence that pain-depressed behaviours should be considered
and evaluated when determining the antinociceptive effects of NMDA
receptor antagonists.
1. Introduction
N-methyl-D-aspartate (NMDA) glutamate receptors
play a key role in transmission of nociceptive infor-
mation in the central nervous system (Bleakman
et al., 2006; Wozniak et al., 2012), and NMDA
receptor antagonists are under consideration as can-
didate analgesics (Niesters and Dahan, 2012). In sup-
port of this consideration, systemic administration of
ketamine or the more selective NMDA antagonist
MK-801 produced antinociception in several preclin-
ical animal models (Millan and Seguin, 1994;
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Fundytus, 2001; Sabetkasaie et al., 2007). However,
the analgesic efficacy of NMDA antagonists in clini-
cal research has been mixed and depends on vari-
ables that include (1) route of administration; (2)
treatment duration; (3) pain state; and (4) pain mea-
surement (Niesters et al., 2014; Sawynok, 2014).
Moreover, the clinical utility of NMDA receptor
antagonists is constrained by concerns regarding side
effects including psychotomimesis and abuse liabil-
ity.
Preclinical studies may help to clarify determinants
of NMDA antagonist analgesic effectiveness, and one
important variable is the behavioural manifestation
of pain under investigation. Virtually all preclinical
studies with NMDA antagonists have employed
assays of pain-stimulated behaviours, which can be
defined as behaviours that increase in frequency,
rate or intensity after delivery of a noxious stimulus
(Negus et al., 2010a; Negus, 2013). In rodents, for
example, ketamine and MK-801 decreased stretching
behaviour stimulated by intraperitoneal acid admin-
istration and flinching behaviours stimulated by for-
malin injection into the hindpaw (Takahashi et al.,
1987; Finck et al., 1988; Millan and Seguin, 1994;
Bulutcu et al., 2002; Sawynok and Reid, 2002;
Malec and Poleszak, 2005; Sabetkasaie et al., 2007).
However, exclusive reliance on assays of pain-stimu-
lated behaviour in preclinical drug evaluation can be
problematic for several reasons. For example, pain-
stimulated behaviours can be reduced not only by
reductions in sensitivity to the noxious stimulus but
also by motor impairment (Negus et al., 2010a).
Novel assays of pain-depressed behaviours have
emerged to complement more conventional proce-
dures (Negus et al., 2010a; Negus, 2013). Pain-
depressed behaviours are defined as behaviours that
decrease in frequency, rate or intensity after delivery
of a noxious stimulus. Assays that measure pain-
depressed behaviours can be useful in part because
pain states often produce clinically relevant impair-
ment of behaviours like feeding, locomotion or posi-
tively reinforced operant behaviour (Cleeland and
Ryan, 1994; Turk et al., 2008).
One recent study reported that ketamine restored
pain-related depression of swimming and sucrose
preference induced in rats by spared nerve injury
(Wang et al., 2011); however, research on NMDA
antagonist effects in assays of pain-depressed beha-
viour is just beginning. This study compared effects
of ketamine and MK-801 in rats using complemen-
tary assays of intraperitoneal acid-stimulated stretch-
ing and acid-depressed intracranial self-stimulation
(ICSS) that have been used to evaluate antinocicep-
tive effects of other drugs including opioids (Pereira
Do Carmo et al., 2009; Negus et al., 2012a, b; Leitl
et al., 2014; Altarifi et al., 2015; Miller et al., 2015a,
b), cannabinoids (Kwilasz and Negus, 2012; Kwilasz
et al., 2014) and monoamine reuptake inhibitors
(Rosenberg et al., 2013; Miller et al., 2015a, b). We
hypothesized that ketamine and MK-801 would
block both acid-stimulated stretching and acid-
induced depression of ICSS.
2. Methods
2.1 Subjects
A total of 26 adult male Sprague–Dawley rats (Har-
lan Laboratories Inc, Frederick, MD, USA) were used
in studies of lactic acid-stimulated stretching
(n = 16) and lactic acid-depressed ICSS (n = 10).
Rats weighed between 300 and 360 g at the time of
surgery, and they were individually housed in plastic
cages in the vivarium with a 12-h light/dark cycle
with lights on 6:00 a.m. All rats had free access to
food and water except during experimental sessions.
Procedures complied with the Guide for the Care and
Use of Laboratory Animals and were approved by the
Virginia Commonwealth University Institutional
Animal Care and Use Committee.
At the beginning of the study, all rats were
implanted with a stainless-steel electrode under
isoflurane anaesthesia as described previously
(Rosenberg et al., 2013; Hillhouse et al., 2014). The
cathode of each electrode (Plastics One, Roanoke,
VA, USA) was 0.25 mm in diameter and covered
with polyamide insulation, except at the flattened
tip. The anode was 0.124 mm in diameter and unin-
sulated. The cathode was implanted in the left med-
ial forebrain bundle at the level of the lateral
hypothalamus (2.8 mm posterior and 1.7 mm lateral
from the bregma, and 8.8 mm below the skull). The
anode was wrapped around one of three skull screws
to serve as the ground, and the skull screws and
electrode assembly were secured with orthodontic
resin. Rats received ketoprofen (5 mg/kg i.p. for
2 days) as a postoperative analgesic and were
allowed to recover for at least 7 days before com-
mencing ICSS training.
2.2 Assay of lactic acid-depressed ICSS
2.2.1 Apparatus
Intracranial self-stimulation studies were conducted
in 12 sound-attenuating chambers that contained
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operant conditioning chambers (29.2 9 30.5 9
24.1 cm) equipped with a response lever (4.5-cm
wide, extended 2.0 cm through the centre of one
wall, 3 cm off the floor), stimulus lights (three lights
coloured red, yellow and green positioned 7.6 cm
directly above the lever), a house light and an ICSS
stimulator (Med-Associates, St Albans, VT, USA).
Electrodes were connected to the stimulator through
bipolar cables and a commutator (Model SL2C; Plas-
tics One). Programming of behavioural sessions and
data collection were computer controlled by Med-
State software (Med PC, Version 4.1; Med-Associ-
ates).
2.2.2 Behavioural procedure
All rats were initially exposed to ICSS training using
procedures similar to those described previously to
establish lever press responding for pulses of electri-
cal brain stimulation (0.5-s train of 0.1 ms square-
wave cathodal pulses) under a fixed-ratio 1 (FR 1)
schedule (Negus and Miller, 2014). During initial
training, the frequency of stimulation was held con-
stant at 158 Hz, and the intensity was adjusted indi-
vidually in each rat to the lowest intensity sufficient
to maintain an ICSS rate >30 stimulations per min-
ute. Frequency manipulations were then introduced,
and the terminal schedule consisted of sequential
10-min components. During each component, a
descending series of 10 brain stimulation frequencies
was presented, with a 60-s trial at each of 10 fre-
quencies (158 to 56 Hz in 0.05-log increments).
Each frequency trial began with a 10-s timeout, dur-
ing which the house light was off and responding
had no scheduled consequences. During the last 5 s
of this timeout, five noncontingent stimulations
were delivered once per second at the frequency
available during that trial, and the lever lights were
illuminated during each stimulation. This noncontin-
gent stimulation was then followed by a 50-s ‘re-
sponse’ period, during which the house light was
illuminated, and each lever press produced electrical
stimulation and illumination for 0.5 s of the
coloured stimulus lights over the lever. Training con-
tinued with presentation of three to six sequential
components per day, and stimulation intensities
were again adjusted individually for each rat, until
rats reliably responded at rates ≥50% maximum con-
trol rates (MCRs; see Data analysis) for at least three
and no more than six trials of all components for at
least three consecutive days. Stimulation intensities
were then held constant for the remainder of the
study in each rat (range: 100–280 lA). In general,
rats were implanted with electrodes and exposed to
ICSS in groups of 12–16, and the first six rats in each
group to meet training criteria advanced to ICSS
pharmacological testing. The remaining rats that
failed to meet training criteria were assigned to
assays of acid-stimulated stretching (see below).
Overall, 10 rats completed ICSS studies and 16 rats
completed stretching studies. Additionally, rats were
habituated to saline injections until these injections
had no significant effect on ICSS frequency-rate
curves as determined by two-way analysis of vari-
ance (ANOVA; see Data Analysis).
Testing was conducted using a within-subject
experimental design that has been used previously
to evaluate antinociceptive effects of other drugs
including opioids (Pereira Do Carmo et al., 2009;
Negus et al., 2012a, b; Leitl et al., 2014; Altarifi
et al., 2015; Miller et al., 2015a, b), cannabinoids
(Kwilasz and Negus, 2012; Kwilasz et al., 2014) and
monoamine reuptake inhibitors (Rosenberg et al.,
2013; Miller et al., 2015a, b). ICSS test sessions for
dose–effect testing consisted of six sequential compo-
nents. The first component of each test session was
considered an acclimation component, and data from
this component were discarded. Data from the sec-
ond and third ‘baseline’ components were used to
calculate control parameters of frequency-rate curves
for that test session in that rat (see Data Analysis).
Immediately after completion of the baseline compo-
nents, rats were taken out of the ICSS chambers,
administered drug or vehicle (i.p.) and placed back
into their home cages. After the designated pretreat-
ment time elapsed, 1.8% lactic acid or its vehicle
was administered i.p. in a volume of 1 mL/kg, and
rats were immediately placed back into the ICSS
chambers for three test components (10 min each,
30 min total). This testing period was chosen to
match the session length for stretching studies (see
below). Doses and pretreatment times (ketamine:
1.0–10.0 mg/kg, 10 min; MK-801: 0.01–0.32 mg/kg,
15 min; ketoprofen: 1.0 mg/kg, 30 min) were based
on empirical results and on previous studies (Negus
et al., 2012a; Hillhouse et al., 2014), and dose order
across rats was counterbalanced using a Latin-square
design. Each drug was tested in a group of five rats.
If ICSS performance remained stable in a given rat
after completion of testing with the initial drug, then
the rat was advanced to testing with the next drug.
There was at least a 7-day washout period between
drugs. For ketamine, all rats were drug na€ıve. For
MK-801, all rats had been tested previously with
ketamine. For ketoprofen, four rats were drug na€ıve,
and one rat had been tested previously with keta-
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mine and MK-801. Testing was conducted twice per
week (typically Tuesday and Friday) with at least
72 h between drug injections. Additionally, 1.8%
lactic acid injections separated by 1 week to match
acid-stimulated stretching studies.
2.2.3 Data analysis
Data were analysed using procedures described pre-
viously (Rosenberg et al., 2013; Negus and Miller,
2014). The primary dependent variable was the rein-
forcement rate in stimulations/trial during each fre-
quency trial. To normalize these raw data,
reinforcement rates from each trial were converted
into the per cent MCR, with MCR defined as the
mean of the maximal number of stimulations/trial
observed in any frequency trial during the second
and third baseline components for each test day in
each rat. Thus, % MCR for each trial was calculated
as (stimulations during a frequency trial/MCR)*100.
Normalized data from the frequency trials of consec-
utive test components were then averaged across rats
for display and for statistical analysis using two-way
repeated measures ANOVA, with drug dose as one
factor and ICSS frequency as the other factor. A sig-
nificant ANOVA was followed by a Holm–Sidak post
hoc test, and the criterion for significance was set at
p < 0.05.
To provide an additional summary of ICSS perfor-
mance, the total number of stimulations delivered
across all 10 frequency trials was determined for
each component. The average number of total stim-
ulations per test component was expressed as a per-
centage of the average number of total stimulations
per component during the second and third baseline
components using the equation % Baseline Total
Stimulations = (average test stimulations per compo-
nent/average baseline stimulations per component)
*100. These values were then averaged across rats in
each experimental condition for visual display. Addi-
tionally, these data were also used to quantify block-
ade of acid-induced depression of ICSS. Specifically,
‘per cent acid blockade’ was quantified using the
equation ([test-acid]/[baseline-acid])*100, where
‘test’ was the total number of ICSS stimulations per
component after treatment with drug + acid, ‘acid’
was the total number of stimulations per component
after treatment with vehicle + acid, and ‘baseline’
was the total number of stimulations per component
during the second and third baseline components
(daily baseline). For all drugs producing dose-depen-
dent effects that exceeded 50% acid blockade, a lin-
ear regression in GraphPad Prism 6.0 (La Jolla, CA,
USA) was used to calculate an ED50 and 95% confi-
dence intervals (CI), with ED50 defined as the effec-
tive dose producing 50% acid blockade. ED50 values
were considered to be significantly different if 95%
CIs did not overlap. A value of 100% acid blockade
indicated complete blockade of acid-induced depres-
sion of ICSS. Values greater than 100% acid block-
ade indicated facilitation of ICSS above baseline
levels, and values below 0% indicated exacerbation
of acid-induced depression of ICSS.
2.3 Assay of lactic acid-stimulated stretching
2.3.1 Behavioural procedure
To complement studies in the assay of acid-depressed
ICSS, 16 rats that failed to meet ICSS training crite-
ria within 4 weeks were used in studies of lactic
acid-stimulated stretching as described previously
(Pereira Do Carmo et al., 2009; Negus et al., 2012a,
b; Rosenberg et al., 2013). During test sessions, each
rat received an i.p. injection of the test drug followed
first by a designated pretreatment interval and then
by i.p. injection of 1.8% lactic acid in a volume of
1 mL/kg. Immediately after the second injection, rats
were placed into an acrylic test chamber
(31.0 9 20.1 9 20.0 cm) for a 30-min observation
period, and the number of stretches was counted. A
stretch was operationally defined as a contraction of
the abdomen followed by extension of the hin-
dlimbs. Drugs, doses and pretreatment times were
identical to those used in studies of acid-depressed
ICSS, and dose order across rats was counterbalanced
using a Latin-square design. Each drug was tested in
a group of seven rats. For ketamine and MK-801, all
rats were drug na€ıve. For ketoprofen, two rats were
drug na€ıve and five rats had been tested previously
with MK-801. Test sessions were conducted once per
week.
2.3.2 Data analysis
The primary dependent variable was the number of
stretches counted during each observation period in
each rat. Raw data were normalized to the vehicle
control in each rat using the equation Per cent Con-
trol Stretching = (drug/vehicle)*100, where ‘drug’
was the number of stretches observed after a test
drug dose + acid, and ‘vehicle’ was the number of
stretches after vehicle + acid. Data for ketamine and
MK-801 were then analysed using a one-way
repeated measures ANOVA with drug dose as the
within-subjects factor, and Holm–Sidak post hoc tests
were conducted after all significant ANOVAs. A
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paired t-test was used for ketoprofen. The criterion
for significance was set to p < 0.05 for all statistical
tests. To calculate the ED50 values and 95% CIs for
ketamine and MK-801, dose–effect data were anal-
ysed by linear regression in GraphPad Prism 6.0, and
the ED50 was defined as the effective dose produc-
ing 50% control stretching.
2.4 Drugs
The noncompetitive NMDA receptor antagonists ()
ketamine HCl and (+) MK-801 hydrogen maleate
(both from Sigma Aldrich, St. Louis, MO, USA) were
dissolved in 0.9% physiological saline. The nons-
teroidal anti-inflammatory drug ketoprofen propi-
onate (Spectrum Chemical, Gardena, CA, USA) was
dissolved in bacteriostatic water. Lactic acid (Sigma
Aldrich) was diluted in bacteriostatic water. All drugs
were administered intraperitoneally at a volume of
1.0 mL/kg.
3. Results
3.1 Effects of noncompetitive NMDA receptor
antagonists on acid-stimulated stretching
Administration of the noxious stimulus (i.p. injection
of 1.0 mL/kg 1.8% lactic acid) produced a
mean  SEM of 15.44  0.88 stretches across all 16
rats. The mean  SEM number of stretches for each
drug vehicle + 1.8% lactic acid were as follows: keta-
mine (n = 7), 14.71  0.88; MK-801 (n = 7),
16.21  2.09; ketoprofen (n = 7), 15.93  1.74.
Fig 1 shows the effects of ketamine, MK-801 and
ketoprofen on per cent control stretching. Ketamine
(1–10 mg/kg) and MK-801 (0.01–0.32 mg/kg) pro-
duced dose-dependent decreases in acid-stimulated
stretching, and ED50 values are shown in Table 1.
The 1.0 mg/kg dose of ketoprofen also significantly
decreased acid-stimulated stretching.
3.2 Effects of noncompetitive NMDA receptor
antagonists on acid-depressed ICSS
Prior to each test session in each rat, a baseline fre-
quency-rate curve was determined to establish the
MCR and total number of stimulations per compo-
nent for that session. Across all 10 rats used in ICSS
studies, the mean  SEM MCR was 60.16  2.69
stimulations per trial, and the mean  SEM total
number of stimulations per component was
261.02  16.75. Fig 2 shows that the acid noxious
stimulus depressed ICSS. Under control conditions
(vehicle + vehicle), electrical brain stimulation main-
tained a frequency-dependent increase in respond-
ing, and treatment with i.p. lactic acid produced a
rightward and downward shift in the ICSS fre-
quency-rate curve and a decrease in total stimula-
tions per component. Specifically, treatment with
lactic acid decreased ICSS rates across the six highest
frequencies (89–158 Hz) and decreased the number
of total stimulations per component to 59% of base-
line.
Fig 3 shows the effects ketamine (n = 5) and MK-
801 (n = 5) on ICSS in the absence and presence of
the noxious stimulus. In the absence of the noxious
stimulus, ketamine depressed ICSS. Treatment with
1.0 and 3.2 mg/kg ketamine had no significant
effect, but 10.0 mg/kg ketamine decreased ICSS rates
across a board range of frequencies (100–141 Hz)
(Fig 3A). When ketamine was administered as a pre-
treatment to lactic acid, ketamine did not signifi-
cantly alter ICSS and failed to block acid-induced
depression of ICSS (Fig 3B). MK-801 also depressed
ICSS in the absence of the noxious stimulus. Treat-
ment with 0.01–0.1 mg/kg MK-801 did not signifi-
Figure 1 Effects of ketamine, MK-801 and ketoprofen on acid-stimu-
lated stretching. Abscissa: Drug dose in mg/kg (log scale). Ordinate:
Per cent control stretching observed after vehicle administration. All
points show mean  SEM for seven rats, and ED50 values are
reported in Table 1. There was a significant main effect of dose for
ketamine (F[3,18] = 34.52, p < 0.001), MK-801 (F[4,24] = 25.12,
p < 0.001) and ketoprofen (t[6] = 7.34, p < 0.001). Filled points indi-
cate significantly different from vehicle control.
Table 1 ED50 values in mg/kg (95% confidence intervals) for the
NMDA antagonists ketamine and MK-801 in the assays of acid-stimu-
lated stretching or acid-depressed ICSS.
Drug Acid-stimulated stretching Acid-depressed ICSS
Ketamine 2.47 (1.84–3.32) Inactive
MK-801 0.036 (0.029–0.045) 0.013 (0.003–0.049)
A single dose of ketoprofen (1.0 mg/kg), therefore an ED50 value was
not calculated for ketoprofen. Inactive indicates a failure to produce
at least 50% acid blockade in acid-depressed ICSS.
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cantly alter ICSS, but 0.32 mg/kg MK-801 depressed
ICSS across the five highest frequencies (100–
158 Hz) (Fig 3D). When MK-801 was administered
as a pretreatment to lactic acid, MK-801 produced
both increasing and decreasing effects on ICSS
(Fig 3E). Specifically, 0.1 mg/kg MK-801 increased
rates of ICSS at intermediate frequencies (100–
112 Hz) to attenuate acid-induced depression of
ICSS. Conversely, 0.32 mg/kg MK-801 exacerbated
acid-induced depression of ICSS at the three highest
frequencies (126–158 Hz).
Fig 4 shows the effects ketoprofen (n = 5) on ICSS
in the absence and presence of the lactic acid nox-
ious stimulus. Ketoprofen (1.0 mg/kg) did not alter
ICSS in the absence of lactic acid (Fig 4A). When
administered as a pretreatment to lactic acid,
1.0 mg/kg ketoprofen ameliorated acid-induced
depression of ICSS (Fig 4B) and increased ICSS rates
across a range of intermediate and high frequencies
(89–141 Hz).
Fig 5 shows the effects of ketamine, MK-801 and
ketoprofen expressed as ‘per cent acid blockade’ on
acid-depressed ICSS. Ketamine failed to attenuate
acid-induced depression of ICSS, and only one dose
of ketoprofen (1.0 mg/kg) was tested; therefore,
ED50 values could not be calculated for these drugs.
MK-801 produced a significant blockade of acid-
depressed ICSS at the 0.1 mg/kg dose, and the ED50
value is shown in Table 1. MK-801 displayed similar
potencies to block acid-induced depression of ICSS
and acid-induced stimulation of stretching as
indicated by overlapping confidence limits for ED50
values.
4. Discussion
The present study compared the antinociceptive
effects of the noncompetitive NMDA receptor antag-
onists ketamine and MK-801 in assays of acid-stimu-
lated stretching and acid-depressed ICSS. There were
three main findings. First, in agreement with previ-
ous studies, both ketamine and MK-801 produced
antinociceptive effects in an assay of pain-stimulated
behaviour, in which ketamine and MK-801 dose-
dependently decreased the number of acid-induced
stretches. Second, MK-801 but not ketamine, pro-
duced antinociceptive effects in the assay of pain-
depressed behaviour; however, the effective dose
range for MK-801 was narrow. Specifically, only the
0.1 mg/kg dose of MK-801 attenuated acid-depressed
ICSS, whereas ketamine failed to alter acid-depressed
ICSS at any dose tested. Furthermore, the high dose
of either ketamine or MK-801 depressed all beha-
viours. Finally, the NSAID ketoprofen attenuated
both acid-stimulated stretching and acid-depressed
ICSS. These results suggest that MK-801 may be
more effective than ketamine to attenuate both
pain-depressed and pain-stimulated behaviours.
4.1 Ketoprofen effects on acid-stimulated
stretching and acid-depressed ICSS
The effectiveness of ketoprofen to block both acid-
stimulated stretching and acid-induced depression of
ICSS agrees with previous studies with ketoprofen in
these two procedures (Kwilasz and Negus, 2012;
Negus et al., 2012a; Leitl et al., 2014) and with the
clinical effectiveness of ketoprofen as a clinically
Figure 2 Acid-induced depression of ICSS. Left panel (A) shows the effects of pretreatment with vehicle + vehicle (Veh + Veh) and vehicle + 1.8%
lactic acid (Veh + 1.8% LA) on full ICSS frequency-rate curves for all 10 rats used in ICSS studies. Abscissa: Frequency of electrical brain stimulation
in Hz (log scale). Ordinate: Per cent maximum control rate (%MCR). Filled points represent frequencies at which ICSS rates after Veh + 1.8% LA
were significantly lower than rates after Veh + Veh as determined by a two-way ANOVA followed by a Holm–Sidak post hoc test, p < 0.05. Right
panel (B) shows summary ICSS data for lactic acid effects on the total number of stimulations per component delivered across all frequencies.
Abscissa: Treatment condition. Ordinate: Per cent baseline stimulations per test component. The downward arrow indicates a significant acid-
induced decrease in ICSS relative to Veh + Veh for at least one brain stimulation frequency as determined by analysis of full frequency-rate curves
in the left panel. All data show mean  SEM for 10 rats. Statistical results for the left panel (A) are as follows: Significant main effect of frequency
(F[9,126] = 226.70, p < 0.001) and treatment (F[1,14] = 184.60, p < 0.001) and a significant interaction (F[9,126] = 14.41, p < 0.001).
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effective analgesic drug under conditions of inflam-
matory pain (Veys, 1991; Caldwell, 1994; Kokki
et al., 1999). Moreover, a similar profile of drug
effects on acid-induced stimulation of stretching and
depression of ICSS has been produced by morphine
and other mu opioid analgesics (Pereira Do Carmo
et al., 2009; Negus et al., 2010b; Leitl et al., 2014;
Altarifi et al., 2015). These results with ketoprofen
as a positive control illustrate the profile of effects
produced by a clinically effective analgesic drug, and
effects of NMDA antagonists were compared to
effects of ketoprofen.
4.2 NMDA receptor antagonist effects on acid-
stimulated stretching
Like ketoprofen, both ketamine and MK-801 dose-
dependently decreased acid-stimulated stretching in
rats. These results are consistent with previous
reports that both noncompetitive and competitive
Figure 3 Effects of the ketamine (A–C) and MK-801 (D–F) on control and acid-depressed ICSS. Left and centre panels show drug effects on full
ICSS frequency-rate curves when drugs were administered as a pretreatment to acid vehicle (left panels A, D) or 1.8% lactic acid (centre panels B,
E). Abscissae: Frequency of electrical brain stimulation in Hz (log scale). Ordinates: Per cent maximum control rate (%MCR). Filled points represent
frequencies at which ICSS rates after test drug treatment were significantly different from rates after treatment with Veh + Veh (A, D) or Veh +
1.8% LA (B, E) as determined by a two-way ANOVA followed by a Holm–Sidak post hoc test, p < 0.05. Right panels (C, F) show summary ICSS data
for drug effects on the total number of stimulations delivered across all frequencies per test component when drugs were administered as a pre-
treatment to acid vehicle (open bars) or 1.8% lactic acid (filled bars). Abscissae: Drug dose (mg/kg). Ordinates: Per cent baseline stimulations per
test component. Upward/downward arrows indicate that the drug dose produced a significant increase/decrease in ICSS for at least one brain
stimulation frequency as determined by analysis of full frequency-rate curves in the left and centre panels. All data show mean  SEM for five
rats. Statistical results for the left and centre panels are as follows: (A) ketamine + vehicle: Significant main effect of frequency (F[9,36] = 120.50,
p < 0.001) and treatment (F[3,12] = 10.22, p = 0.001) and a significant interaction (F[27,108] = 2.88, p < 0.001). (B) ketamine +1.8% LA: Significant
main effect of frequency (F[9,36] = 42.15, p < 0.001) but not dose (F[3,12] = 0.50, p = 0.69); the interaction was not significant (F[27,108] = 0.39,
p = 0.99). (D) MK-801 + vehicle: Significant main effect of frequency (F[9,36] = 117.00, p < 0.001) and treatment (F[4,16] = 19.41, p < 0.001) and a
significant interaction (F[36,144] = 8.13, p < 0.001). (E) MK-801 +1.8% LA: Significant main effect of frequency (F[9,36] = 57.40, p < 0.001) and dose
(F[4,16] = 10.05, p < 0.001) and a significant interaction (F[36,144] = 8.40, p < 0.001). *Indicates significantly different from Veh + Veh in the right
panels as determined by a paired t-test (p < 0.05).
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NMDA receptor antagonists produce antinociceptive
effects in assays of pain-stimulated behaviours. For
example, the noncompetitive NMDA receptor antag-
onists ketamine (Ryder et al., 1978; Takahashi et al.,
1987; Finck et al., 1988; Bulutcu et al., 2002; Jahan-
giri et al., 2013), MK-801 (Millan and Seguin, 1994;
Seguin et al., 1995; Malec and Poleszak, 2005;
Suardıaz et al., 2007) and memantine (Millan and
Seguin, 1994), and the competitive NMDA receptor
antagonists CGS 19755 and CPP (3-((+)-2-carboxypi-
perazin-4-yl)-propyl-l-phosphonic acid) (Millan and
Seguin, 1994) attenuate acid-stimulated stretching in
mice. Moreover, these same NMDA antagonists have
also been shown to block formalin-induced stimula-
tion of paw licking and flinching in mice (Millan
and Seguin, 1994; Seguin et al., 1995; Bulutcu et al.,
2002; Sabetkasaie et al., 2007). In rodent models of
neuropathic pain, NMDA receptor antagonist also
decrease hypersensitive paw withdrawal responses
induced by application of thermal and mechanical
stimuli (Christoph et al., 2006; Swartjes et al., 2011;
Andreasen et al., 2013). Reductions in these pain-sti-
mulated behaviours are often interpreted as
antinociceptive effects; however, drug-induced
decreases in pain-stimulated behaviours may reflect
impaired ability to emit the motor response rather
than reduced sensitivity to the noxious stimulus.
Consistent with this possibility, the doses of MK-801
and ketamine that produced maximal decreases in
stretching (0.32 and 10 mg/kg, respectively) in the
present study also produced significant decreases in
ICSS. Thus, in the present study, we evaluated the
effects of ketamine and MK-801 on pain-depressed
behaviours to provide additional insight into the
antinociceptive profile of these NMDA receptor
antagonists.
4.3 NMDA receptor antagonist effects on acid-
induced depression of ICSS
Similar to ketoprofen, MK-801 block acid-induced
depression of ICSS as well as acid-stimulated stretch-
ing suggesting that MK-801 did produce an antinoci-
ceptive decrease in sensitivity to the acid noxious
stimulus. This finding supports further consideration
of NMDA receptor antagonists as candidate anal-
Figure 4 Effects of ketoprofen on control and acid-depressed ICSS. Left and centre panels show drug effects on full ICSS frequency-rate curves
when ketoprofen or its vehicle was administered as a pretreatment to acid vehicle (left panel A) or 1.8% lactic acid (centre panel B). Filled points
represent frequencies at which ICSS rates after ketoprofen treatment were significantly different from rates after Veh + Veh (A) or Veh + 1.8% LA
(B) as determined by a two-way ANOVA followed by a Holm–Sidak post hoc test, p < 0.05. Right panel (C) shows summary ICSS data for drug
effects on the total number stimulations delivered across all frequencies per test component when ketoprofen was administered as a pretreatment
to acid vehicle (open bars) or 1.8% lactic acid (filled bars). Other details as in Fig. 3. All data show mean  SEM for five rats. Statistical results for
the left and centre panels are as follows: (A) ketoprofen + vehicle: Significant main effect of frequency (F[9,36] = 44.79, p < 0.001) but not treat-
ment (F[1,4] = 0.12, p = 0.74); the interaction was not significant (F[9,36] = 0.79, p = 0.63). (B) ketoprofen + 1.8% LA: Significant main effect of fre-
quency (F[9,36] = 45.63, p < 0.001) and treatment (F[1,4] = 60.63, p = 0.001) and a significant interaction (F[9,36] = 2.82, p < 0.05). *Indicates
significantly different from Veh + Veh in the right panels as determined by a paired t-test (p < 0.05).
Figure 5 Effects of ketamine, MK-801 and ketoprofen on acid-
depressed ICSS expressed as % acid blockade. Abscissa: Drug dose
(mg/kg). Ordinate: Per cent blockade of acid-induced depression of
ICSS. All data show mean  SEM for five, and ED50 values are
reported in Table 1.
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gesics. However, it should be noted that MK-801
had a narrow therapeutic window, and only 0.1 mg/
kg significantly attenuated both acid-induced stimu-
lation of stretching and depression of ICSS. A higher
dose of 0.32 mg/kg produced a greater reduction in
acid-stimulated stretching but also depressed ICSS in
the absence of the noxious stimulus and exacerbated
acid-induced depression of ICSS, suggesting that this
high MK-801 dose produced general motor impair-
ment.
In contrast to the effects of ketoprofen and MK-
801, ketamine failed to exert a significant effect on
acid-depressed ICSS. The inability of ketamine to
attenuate acid-induced depression of ICSS in the
present study contrasts the finding that ketamine
attenuated pain-related depression of sucrose
preference and swimming behaviour in a spared
nerve injury model of neuropathic pain in rats
(Wang et al., 2011). A major difference between
these studies is the type of pain state used to
produce a depression of behaviours. Specifically, in
the present study, we used an acute visceral nox-
ious stimulus to depress ICSS, whereas Wang et al.
(2011) used a neuropathic manipulation (i.e.
spared nerve injury) to depress sucrose preference
and swimming behaviour. Consequently, these
results suggest that ketamine may be more effec-
tive to alleviate manifestations of sustained neuro-
pathic pain than acute pain. Similar results have
been found in clinical research such that ketamine
may be more effective for neuropathic pain (Back-
onja et al., 1994; Felsby et al., 1996; Leung et al.,
2001; Jørum et al., 2003), spinal cord injuries
(Amr, 2010; Kim et al., 2013) and complex regio-
nal pain syndrome (Schwartzman et al., 2009;
Sigtermans et al., 2009) as compared to visceral
pain states. For example, several small sample
(n = 6–12) double-blind clinical studies found that
a single intravenous infusion of ketamine can
reduce allodynia, hyperalgesia and spontaneous/on-
going pain in patients suffering from neuropathic
pain (Backonja et al., 1994; Felsby et al., 1996;
Leung et al., 2001; Jørum et al., 2003). On the
other hand, oral administration of the more potent
isomer S-ketamine (25 or 50 mg) did not alter
pain scores in a gastric-distension model of acute
visceral pain (Kuiken et al., 2004). Similar to keta-
mine, selective serotonin or norepinephrine reup-
take inhibitors (Rosenberg et al., 2013),
cannabinoid 1 receptor agonists (Kwilasz and
Negus, 2012), endocannabinoid enzyme inhibitors
(Kwilasz et al., 2014) and kappa opioid agonists
(Negus et al., 2010b, 2012a) all fail to block acid-
depressed ICSS, but are successful at blocking acid-
stimulated stretching.
The present results in the assay of acid-depressed
ICSS suggest a dissociation in effects of MK-801 and
ketamine despite the general categorization of both
drugs as NMDA receptor antagonists. Moreover, a
similar dissociation of behavioural effects of MK-801
and ketamine has been shown in rats in assays of
conditioned and unconditioned behaviours (McMil-
lan et al., 1992; Gilmour et al., 2009; Smith et al.,
2011; Hillhouse and Porter, 2014). The pharmacolog-
ical differences in affinity and selectivity of MK-801
and ketamine for NMDA receptors may account for
the behavioural difference found in the present and
previous studies. For example, MK-801 binds to
NMDA receptors with high affinity (Ki = 2.5 nM)
and selectively (Bresink et al., 1995; Nishimura
et al., 1998a), whereas ketamine has low affinity
(Ki = 1.190 nM) for NMDA receptors and apprecia-
ble affinity for several G-protein-coupled receptors
(GPCRs). For example, ketamine binds to mu
(Ki = 26.8 lM), kappa (Ki = 85.2 lM) and delta
(Ki = 101.0 lM) opioid receptors as well as mus-
carinic M1 (Ki = Ki = 45.0 lM) and sigma receptors
(Ki = 66.0 lM) (Smith et al., 1987; Bresink et al.,
1995; Hirota et al., 2002). Furthermore, ketamine
has been shown to inhibit norepinephrine and dopa-
mine transporters (Nishimura et al., 1998b). Keta-
mine is only 20- to 60-fold more selective for the
NMDA receptor over these other GPCRs and trans-
porters, whereas MK-801 is more than 1500-fold
more selective for NMDA receptor as compared to
these other receptors. Thus, it is possible that keta-
mine is producing ‘off-target’ effects at one or more
of these receptors.
4.4 NMDA antagonist effects on ICSS in the
absence of the noxious stimulus
The present dissociation of MK-801 and ketamine
effects on acid-induced depression of ICSS is also
consistent with a dissociation in MK-801 and keta-
mine effects on ICSS in the absence of a noxious
stimulus. Specifically, many drugs of abuse increase
low ICSS rates maintained by low frequencies or
intensities of brain stimulation, and this drug-
induced ‘facilitation’ of ICSS is often interpreted as
evidence of abuse potential (Carlezon and Chartoff,
2007; Negus and Miller, 2014). Both MK-801 and
ketamine effects on ICSS have been evaluated in
this context, and MK-801 is more likely than keta-
mine to produce ICSS facilitation (Corbett, 1989;
Herberg and Rose, 1989; Carlezon and Wise, 1993;
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Bespalov et al., 1999; Hillhouse et al., 2014). For
example, we reported previously that MK-801 doses
of 0.1–0.18 mg/kg facilitated ICSS, whereas no keta-
mine dose from 1.0 to 10 mg/kg facilitated ICSS
(Hillhouse et al., 2014). In the present study, the
0.18 mg/kg MK-801 dose was not tested, and other
doses did not significantly facilitate ICSS; however,
lower MK-801 doses did produce a trend towards
ICSS facilitation in the present study (Fig. 3D–F),
and these effects met criteria for statistical signifi-
cance in our previous study. Conversely, ketamine
failed to produce even a trend towards ICSS facilita-
tion in either study. Although ketamine is desig-
nated as a Schedule III drug by the Drug
Enforcement Agency and considered a drug of
abuse, the illicit use of ketamine is small compared
to other drugs of abuse like marijuana, nonprescrip-
tion opioids and stimulants (Center for Behavioral
Health Statistics and Quality, 2015). Additionally,
social context appear to play a major role in the illi-
cit use of ketamine. These results that ketamine
does not facilitate ICSS, but is abuse in humans,
parallel the ICSS results found with D9-tetrahydro-
cannabinol (D9-THC), which also fails to facilitate
ICSS (Kwilasz and Negus, 2012). Overall, the pre-
sent and previous studies are consistent with the
conclusion that MK-801 can produce modest ICSS
facilitation across a narrow range of intermediate
doses, whereas ketamine does not.
5. Conclusion
In conclusion, this study adds to the growing body
of literature examining the antinociceptive effects of
NMDA receptor antagonists on pain-stimulated and
pain-depressed behaviours. Specifically, the present
study supports further consideration of NMDA recep-
tor antagonists as analgesics; however, NMDA recep-
tor antagonists with high affinity and selectivity for
NMDA receptors (e.g. MK-801) may be more effica-
cious at attenuating pain-depressed behaviours as
compared to NMDA receptor antagonists with lower
affinity and selectivity (e.g. ketamine). Moreover,
these results suggest that NMDA receptor antagonists
like MK-801 can produce analgesic effects at doses
that produce relatively weak evidence for abuse
potential.
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